Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback